News & Analysis as of

Biotechnology United Kingdom

White & Case LLP

Transatlantic M&A bull run set for comeback

White & Case LLP on

Encouraged by the relative strength of the dollar and improving financing conditions, US bidders are snapping up European assets - Transatlantic M&A was enjoying record-high activity before the war in Ukraine sparked...more

Hogan Lovells

Successful product launches across the EU, UK, and U.S.

Hogan Lovells on

We were pleased to welcome industry leaders to our Life Sciences and Health Care Horizons event in Boston for the first time since the pandemic. At the event, Hogan Lovells attorneys Eliza Andonova, Ina Brock, Kristin...more

White & Case LLP

Global healthcare M&A delivers strong performance

White & Case LLP on

Dealmaking in the pharma, medical and biotech (PMB) subsectors was driven by both old and new market trends in 2022 - Following a ground-breaking year for dealmaking in 2021, global healthcare M&A remained robust in 2022,...more

Dechert LLP

Life Sciences Sector Vision

Dechert LLP on

On 7 July 2021, the UK government (the “Government”) published the UK Life Sciences Vision (the “Vision”) setting out a 10-year strategy for the UK life sciences sector “to solve some of the biggest healthcare problems of our...more

Dechert LLP

UK Life Sciences and Healthcare Newsletter- December 2020: Regulatory Updates

Dechert LLP on

Medicines and Medical Devices Bill (MMDB) – The MMDB is intended to act as the primary UK legislation specifying powers that would enable the regulatory regimes for human medicines, clinical trials, veterinary medicines and...more

Dechert LLP

UK Life Sciences and Healthcare Newsletter - December 2020: The UK National Security and Investment Bill

Dechert LLP on

The UK has announced a bill proposing a new system to screen transactions for national security risk, separate from the system of merger review operated by the Competition and Markets Authority. The National Security and...more

Morgan Lewis

COVID-19 Vaccine: Considerations for UK Employers

Morgan Lewis on

The eagerly anticipated news of coronavirus (COVID-19) vaccine candidates last week has been welcomed by the scientific community across the globe. For employers, the news has prompted consideration of the potential...more

A&O Shearman

Covid-19 coronavirus – the UK’s preparation for a vaccine

A&O Shearman on

The UK’s vaccine portfolio The UK Government has agreed supply deals for at least 340 million doses of six different vaccines, with most likely to require two doses: The vaccines are based on a range of vaccine technologies...more

Goodwin

Global Trends and Opportunities in Life Sciences Real Estate – Spotlighting the U.S. and the UK

Goodwin on

An aging global population, a once-in-a-century pandemic and the continued convergence of scientific breakthroughs like cell and gene therapies and artificial intelligence are among just a few of the key factors that continue...more

Dechert LLP

UK Life Sciences and Healthcare Newsletter - August 2020: COVID-19 – How Have Listed Companies Fared?

Dechert LLP on

COVID-19 has had a significant financial impact on many listed companies and, in recent months, there has been a marked increase in equity capital raises by listed companies. As at 22 July 2020, there have been over 100...more

Dechert LLP

Increased regulatory scrutiny of foreign direct investments in the healthcare sector

Dechert LLP on

Key Takeaways - - Foreign Direct Investment (FDI) controls are proliferating around the globe. Since the pandemic, “health” has become a particular focus.  - Several countries have adapted their existing FDI rules, or...more

Hogan Lovells

The global impact of COVID-19 on clinical trials and countermeasure development

Hogan Lovells on

The World Health Organization (WHO) has determined that the 2019 novel coronavirus is a “global pandemic” and President Trump has declared a national emergency as the impact of the virus on all aspects of daily life continues...more

Robins Kaplan LLP

Financial Daily Dose 10.29.2019 | Top Story: AT&T Reaches Accord with Elliott Management to End Activist Challenge

Robins Kaplan LLP on

AT&T announced yesterday that it’s resolved an ongoing battle with activist Paul Singer and his Elliott Management by agreeing to keep CEO Randall Stephenson on the job through “at least 2020,” with the chair and CEO roles to...more

Bergeson & Campbell, P.C.

U.K. Announces Open Consultation Call For Evidence To Develop Standards For Compostable, And Biobased Plastics

On July 22, 2019, the United Kingdom (U.K.) Department for Business, Energy and Industrial Strategy and Department for Environment, Food and Rural Affairs announced an open consultation for the development of standards for...more

McDermott Will & Emery

Digital Health in the United Kingdom: The New Regulatory Environment Under the Medical Device Regulation

The MDR and other recent developments in the health care regulatory landscape pose new opportunities and challenges for medical software companies and investors in digital health in the United Kingdom. Although the regulatory...more

American Conference Institute (ACI)

[Event] Pharmaceutical Patent Term Extensions – The Only Specialized Forum on SPCs and Patent Protection in Europe and Around the...

This year’s C5’s Pharma Patent Term Extensions Forum arrives at a critical time for the pharmaceutical industry. Overarching developments from the Teva U.K. decision (C-121/17) to the SPC Manufacturing Waiver and the most...more

Hogan Lovells

Brexit: the impact on supplementary protection certificates (SPCs)

Hogan Lovells on

On 6 February 2019 the House of Commons and House of Lords approved The Patents (Amendment) (EU Exit) Regulations 2018 (Patent SI), which, if it is signed into law, will come into force on Brexit day (i.e. 29 March 2019 or...more

Bergeson & Campbell, P.C.

University Of Manchester Is Awarded £10 Million For A Biomanufacturing Research Hub

On February 13, 2019, the University of Manchester was awarded £10 million by the English government. These funds are to be used in the launching of a country-wide biomanufacturing research hub to lead the way in new...more

Hogan Lovells

New Brexit Q&A provides several examples in relation to the “placing on the EU market” of products including medical devices

Hogan Lovells on

On 1 February 2019, the European Commission published a new Q&A document to give further guidance on the Notice to stakeholders-withdrawal of the United Kingdom and EU rules in the field of industrial products (“the Notice”)....more

American Conference Institute (ACI)

[Event] 11th Pharma & Biotech Patent Litigation - February 26 - 27, 2019 - Radisson Blu Hotel, Amsterdam

The annual gathering exploring the inherently complex and continually contentious pharma and biotech patent litigation - Life Science patent litigation filings are predicted to rise at new levels. Be part of the only event...more

Bergeson & Campbell, P.C.

UK Publishes Policy Paper On Resources And Waste Strategy

On December 18, 2018, the Department for Environment, Food & Rural Affairs and the Environment Agency of the United Kingdom (UK) published a policy paper titled “Our Waste, Our Resources: A Strategy for England.” The paper...more

Hogan Lovells

Effects of Brexit on reimbursement decisions concerning medicinal products in Poland

Hogan Lovells on

The President of the Office for the Registration of Medicinal Products, Medical Devices, and Biocidal Products (URPL) estimates that approximately 20% of all the 10,000 medicinal products registered in Poland will be affected...more

Bergeson & Campbell, P.C.

UK’s Bioeconomy Policy In Years To Come

On December 5, 2018, the United Kingdom (UK) published a policy paper titled “Growing the Bioeconomy, Improving Lives and Strengthening Our Economy: A National Bioeconomy Strategy to 2030.”...more

Shook, Hardy & Bacon L.L.P.

Food & Beverage Litigation Update | November 2018

LEGISLATION, REGULATIONS & STANDARDS - FDA Announces Plan to “Advance Plant, Animal Biotechnology Innovation” - U.S. Food and Drug Administration (FDA) Commissioner Scott Gottlieb has issued a statement announcing the...more

Hogan Lovells

HMA-EMA’s work programme on availability of authorised medicines for human and veterinary use includes measures for Brexit

Hogan Lovells on

On 23 August 2018, the European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA), the network of the National Competent Authorities in the European Economic Area (EEA), published the work programme of their...more

39 Results
 / 
View per page
Page: of 2

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide